Skip to main content

Advertisement

SpringerLink
Log in

Construction and Evaluation of Hyaluronic Acid–Coated Flurbiprofen-Layered Double Hydroxide Ocular Drug Delivery System

  • Research Article
  • Advancements in Modified-release Oral Drug Delivery - Delivery throughout the Gastro-intestinal Tract
  • Published:
AAPS PharmSciTech Aims and scope Submit manuscript

Abstract

In this study, flurbiprofen (FB) was selected as the model drug, and hyaluronic acid–coated flurbiprofen-layered double hydroxide ophthalmic drug delivery system (HA-FB-LDH) was designed and prepared. In this system, the model drug flurbiprofen was intercalated in layered double hydroxide and coated with hyaluronic acid (HA), so as to prolong the corneal residence time and increase the corneal permeability of the drug. Layered double hydroxide (LDH) was prepared by alcohol-water coprecipitation method. Through single factor investigation, the optimum preparation conditions were obtained as follows: The Mg/Al ratio was 2:1, the reaction pH was 11.0, the hydrothermal reaction time was 24 h, and the hydrothermal reaction temperature was 100°C. Under these conditions, the particle size of LDH was 116.4 ± 0.8 nm, the potential was 42.2 ± 1.2 mV, and a relatively regular crystal structure could be had. Then FB was intercalated into the LDH layer to prepare flurbiprofen-layered double hydroxide (FB-LDH). In the end, HA-FB-LDH was prepared by the stirring-ultrasonic method, in which through prescription screening, the molecular weight of HA was 200–400 kDa and the concentration of HA solution was 1.25 mg·mL −1, the final particle size of HA-FB-LDH was 185.8 ± 3.3 nm, and potential of − 31.4 ± 0.7 mV. The successful loading of FB and the coating of HA were verified by XRD, FTIR, TGA, TEM, and other characterization methods. The results of in vitro stability experiment indicated that the coating of HA could significantly enhance the stability of LDH in the presence of electrolytes. The in vitro release results suggested that the cumulative release amounts of FB-LDH and HA-FB-LDH within 12 h were 92.99 ± 0.37% and 74.82 ± 0.29% respectively, showing a certain sustained release effect. At the same time, the release mechanism of FB-LDH was preliminarily explored by in vitro release experiment, which proved that the release mechanism of FB-LDH was mainly ion exchange. The results of in vivo ocular irritation experiments demonstrated that the ophthalmic preparation studied in this paper was safe and non-irritating. The results of tear pharmacokinetics in rabbits showed that the area under the curve(AUC), the average residence time (MRT), and the highest concentration (Cmax) in tears in the HA-FB-LDH group were 4.43, 4.48, and 2.27 times higher than those in eye drops group separately. Furthermore, the AUC of the HA-FB-LDH group was 1.48 times higher than that of the FB-LDH group. The above results suggested that HA-FB-LDH could improve the precorneal residence time. The results of aqueous humor pharmacokinetics in rabbits indicated that the AUC, MRT, and maximum concentration (Cmax) in aqueous humor in the HA-FB-LDH group were 6.88, 2.15, and 4.08 times of those in the eye drop group respectively. Additionally, the AUC and MRT of the HA-FB-LDH group were 1.55 and 1.63 times those of the FB-LDH group separately. These mentioned findings verified that HA-FB-LDH could enhance the corneal permeability of the drug. The fluorescent substance-fluoresce isothiocyanate (FITC) was substituted for FB intercalation in LDH for in vitro tissue imaging study of rabbits, whose results stated clearly that FITC-LDH and HA-FITC-LDH could both prolong the precorneal residence time of drugs, and HA-FITC-LDH could increase the corneal permeability of the drug to a certain extent. To sum up, HA-FB-LDH, which can overcome the shortcomings of low bioavailability of traditional eye drops to a certain degree, is a safe and effective ophthalmic drug delivery system.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

References

  1. Stem cell treatment in retinal diseases. recent developments[J]. Turk J Ophthalmol. 2018;48(1):33–8.

    Google Scholar 

  2. Jumelle C, Gholizadeh S, Annabi N, et al. Advances and limitations of drug delivery systems formulated as eye drops[J]. J Control Release. 2020;321:1–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Javed A, Mohd F, Mohd Q, et al. Colloidal drug delivery system: amplify the ocular delivery[J]. Drug Deliv. 2016;23(3):710–26.

    Google Scholar 

  4. Awwad S, Mohamed Ahmed AHA, Sharma G, Heng JS, Khaw PT, Brocchini S, Lockwood A. Principles of pharmacology in the eye[J]. Br J Pharmacol Chemother. 2017;174(23):4205–23.

    Article  CAS  Google Scholar 

  5. Gause S, Hsu K-H, Shafor C, et al. Mechanistic modeling of ophthalmic drug delivery to the anterior chamber by eye drops and contact lenses[J]. Adv Coll Interface Sci. 2016;233:139–54.

    Article  CAS  Google Scholar 

  6. Ghate E. Ocular drug delivery[J]. Expert Opin Drug Deliv. 2006;3(2):275–87.

    Article  CAS  PubMed  Google Scholar 

  7. Worakul N, Robinson JR. Ocular pharmacokinetics/pharmacodynamics[J]. Eur J Pharm Biopharm. 1997;44(1):71–83.

    Article  CAS  Google Scholar 

  8. Janagam DR, Wu L, Lowe TL. Nanoparticles for drug delivery to the anterior segment of the eye[J]. Adv Drug Delivery. 2017:31–64.

  9. Durak S, Rad ME, Yetisgin AA, et al. Niosomal drug delivery systems for ocular disease—recent advances and future prospects[J]. Nanomaterials. 2020;10(6):1191.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. DelMonte DW, Terry K. Anatomy and physiology of the cornea[J]. J Cataract Refract Surg. 2011;37(3):588–98.

    Article  PubMed  Google Scholar 

  11. Dastjerdi MH, Sadrai Z, Saban DR, et al. Corneal penetration of topical and subconjunctival bevacizumab[J]. Invest Ophthalmol Vis Sci. 2011;52(12):8718–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Mitra AK, Anand BS, Duvvuri S. Drug Delivery to the Eye[J]. Adv Organ Biol. 2005;10:307–51.

    Article  Google Scholar 

  13. Ashaben P, Kishore C, Vibhuti A, et al. Ocular drug delivery systems: an overview[J]. World J Pharmacol. 2013;2(2):47–64.

    Article  Google Scholar 

  14. Bochot A, Fattal E. Liposomes for intravitreal drug delivery: a state of the art[J]. J Control Release. 2012;161(2):628–34.

    Article  CAS  PubMed  Google Scholar 

  15. Imran A, Gokhale DR, Shah VM, et al. Physicochemical determinants of drug diffusion across the conjunctiva, sclera, and cornea[J]. Elsevier. 1987, 76(8): 583–586.

  16. Jamil S, Alvi AR, Khan SR, et al. Synthesis and application of layered double hydroxides (LDHs) [J]. Adv Chem. 2019;31(Z1):394–412.

    CAS  Google Scholar 

  17. Irshad M, Aman G, Singh AJ, et al. Starch-Mg/Al layered double hydroxide composites as an efficient solid phase extraction sorbent for non-steroidal anti-inflammatory drugs as environmental pollutants[J]. J Hazard Mater. 2021;401:123782.

    Article  Google Scholar 

  18. Mei X, Xu S, Hu T, et al. Layered double hydroxide monolayers for controlled loading and targeted delivery of anticancer drugs[J]. Nano Res. 2018;11(1):1998–124.

    Article  Google Scholar 

  19. Fayyazbakhsh F, Solati-Hashjin M, Keshtkar A, et al. Release behavior and signaling effect of vitamin D3 in layered double hydroxides-hydroxyapatite/gelatin bone tissue engineering scaffold: An in vitro evaluation[J]. Colloids Surf B Biointerfaces. 2017;158:697–708.

    Article  CAS  PubMed  Google Scholar 

  20. Wang J, Zhang W, Hao L, et al. Amino acid–intercalated layered double hydroxide core @ ordered porous silica shell as drug carriers: design and applications[J]. J Mater Res. 2019;34(22):3747–56.

    Article  CAS  Google Scholar 

  21. Li Y, Bao W, Wu H, et al. Delaminated layered double hydroxide delivers DNA molecules as sandwich nanostructure into cells via a non-endocytic pathway[J]. Sci Bull. 2017;62(10):686–92.

    Article  CAS  Google Scholar 

  22. Hsiao-Yin Y, Van Ee RJ, Klaas T, et al. A novel injectable thermoresponsive and cytocompatible gel of poly(N-isopropylacrylamide) with layered double hydroxides facilitates siRNA delivery into chondrocytes in 3D culture[J]. Acta Biomater. 2015, 23: 214–228.

  23. Timóteo TRR, Melo CGD, Danda LJDA, et al. Layered double hydroxides of CaAl: a promising drug delivery system for increased dissolution rate and thermal stability of praziquantel[J]. Appl Clay Sci. 2019;180:105197.

    Article  Google Scholar 

  24. Wang Y, Zhou L, Fang L, et al. Multifunctional carboxymethyl chitosan derivatives-layered double hydroxide hybrid nanocomposites for efficient drug delivery to the posterior segment of the eye[J]. Acta Biomater. 2020;104:104–14.

    Article  CAS  PubMed  Google Scholar 

  25. Ameena Shirin VK, Renu S, Johnson AP, et al. Advanced drug delivery applications of layered double hydroxide[J]. J Control Release. 2021;330:398–426.

    Article  CAS  PubMed  Google Scholar 

  26. Jin W, Ha S, Myung J-H, et al. Ceramic layered double hydroxide nanohybrids for therapeutic applications[J]. J Korean Ceram Soc. 2020;57:597–607.

    Article  CAS  Google Scholar 

  27. Mishra G, Dash B, Pandey S. Layered double hydroxides: a brief review from fundamentals to application as evolving biomaterials[J]. Appl Clay Sci. 2018;153:172–86.

    Article  CAS  Google Scholar 

  28. Chaara D, Pavlovic I, Bruna F, et al. Removal of nitrophenol pesticides from aqueous solutions by layered double hydroxides and their calcined products[J]. Appl Clay Sci. 2010;50(3):292–8.

    Article  CAS  Google Scholar 

  29. Vial S, Forano C, Shan D, et al. Nanohybrid-layered double hydroxides/urease materials: Synthesis and application to urea biosensors[J]. Mater Sci Eng C. 2005;26(2):387–93.

    Google Scholar 

  30. Hu Z, Cai L, Liang J, et al. Green synthesis of expanded graphite/layered double hydroxides nanocomposites and their application in adsorption removal of Cr(VI) from aqueous solution[J]. J Clean Prod. 2019;209:1216–27.

    Article  CAS  Google Scholar 

  31. Bashi AM, Hussein MZ, Zainal Z, et al. Simultaneous intercalation and release of 2,4-dichloro- and 4- chloro-phenoxy acetates into Zn/Al layered double hydroxide[J]. Arab J Chem. 2016;9:1457–63.

    Article  Google Scholar 

  32. Sugano K, Kansy M, Artursson P, et al. Coexistence of passive and carrier-mediated processes in drug transport[J]. Nat Rev Drug Discov. 2010;9(Suppl. 4):597–614.

    Article  CAS  PubMed  Google Scholar 

  33. Wong Y, Markham K, Xu ZP, et al. Efficient delivery of siRNA to cortical neurons using layered double hydroxide nanoparticles[J]. Biomaterials. 2010;31(33):8770–9.

    Article  CAS  PubMed  Google Scholar 

  34. Cao F, Wang Y, Ping Q, et al. Zn–Al–NO 3 -layered double hydroxides with intercalated diclofenac for ocular delivery[J]. Int J Pharm. 2011;404(1–2):250–6.

    Article  CAS  PubMed  Google Scholar 

  35. Kang H, Shu Y, Li Z, et al. An effect of alginate on the stability of LDH nanosheets in aqueous solution and preparation of alginate/LDH nanocomposites[J]. Carbohyd Polym. 2014;100:158–65.

    Article  CAS  Google Scholar 

  36. Zi G, Huali Z, Li L, et al. Pre-coating layered double hydroxide nanoparticles with albumin to improve colloidal stability and cellular uptake[J]. J Mater Chem B. 2015;3(16):3331–9.

    Article  Google Scholar 

  37. Toole BP. Hyaluronan: from extracellular glue to pericellular cue[J]. Nat Rev Cancer. 2004;4(7):528–39.

    Article  CAS  PubMed  Google Scholar 

  38. Platt VM, Szoka CF. Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor[J]. Mol Pharm. 2008;5(4):474–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Lerner LE, Schwartz DM, Hwang DG, et al. Hyaluronan and CD44 in the Human Cornea and Limbal Conjunctiva[J]. Exp Eye Res. 1998;67(4):481–4.

    Article  CAS  PubMed  Google Scholar 

  40. Zhu S-N, Nölle B, Duncker G. Expression of adhesion m olecule CD44 on human corneas[J]. Br J Ophthalmol. 1997;81(1):80–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Almalik A, Donno R, Cadman CJ, et al. Hyaluronic acid-coated chitosan nanoparticles: molecular weight-dependent effects on morphology and hyaluronic acid presentation[J]. J Control Release. 2013;172(3):1142–50.

    Article  CAS  PubMed  Google Scholar 

  42. Mizrahy S, Raz SR, Hasgaard M, et al. Hyaluronan-coated nanoparticles: the influence of the molecular weight on CD44-hyaluronan interactions and on the immune response[J]. J Control Release. 2011;156(2):231–8.

    Article  CAS  PubMed  Google Scholar 

  43. Kalam MA. Development of chitosan nanoparticles coated with hyaluronic acid for topical ocular delivery of dexamethasone[J]. Int J Biol Macromol. 2016;89:127–36.

    Article  PubMed  Google Scholar 

  44. Silva M, Calado R, Marto J, et al. Chitosan nanoparticles as a mucoadhesive drug delivery system for ocular administration[J]. Multidisciplinary Digital Publishing Institute. 2017;15(12):370.

  45. Alvarez-Trabado J, López-Garcaí A, Martní-Pastor M, et al. Sorbitan ester nanoparticles (SENS) as a novel topical ocular drug delivery system: design, optimization, and in vitro/ex vivo evaluation[J]. Int J Pharm. 2018;546(1–2):20–30.

    Article  CAS  PubMed  Google Scholar 

  46. Soleymani M, Velashjerdi M, Shaterabadi Z, et al. One-pot preparation of hyaluronic acid-coated iron oxide nanoparticles for magnetic hyperthermia therapy and targeting CD44-overexpressing cancer cells[J]. Carbohyd Polym. 2020;237:116130.

    Article  CAS  Google Scholar 

  47. Atİroğlu V. Lipase immobilization on synthesized hyaluronic acid-coated magnetic nanoparticle- functionalized graphene oxide composites as new biocatalysts: Improved reusability, stability, and activity[J]. Int J Biol Macromol. 2020;145:456–65.

    Article  PubMed  Google Scholar 

  48. Boddeda B, Boddu P, Avasarala H, et al. Design and ocular tolerance of flurbiprofen loaded nanosuspension[J]. Pharm Nanotechnol. 2015;3(1):56–67.

    Article  CAS  Google Scholar 

  49. Agrawal R, Lee CS, Gonzalez-Lopez JJ, et al. Flurbiprofen: a nonselective cyclooxygenase (COX) inhibitor for treatment of noninfectious, non-necrotizing anterior scleritis[J]. Ocul Immunol Inflamm. 2016;24(1):35–42.

    Article  CAS  PubMed  Google Scholar 

  50. Gan L. Development and trend of non-steroidal anti-inflammatory drugs in foreign countries [J]. Chin J New Drugs. 1994;04:53–62.

    Google Scholar 

  51. Golovin SN, Yapryntsev MN, Ryl’tsova IG, et al. Synthesis and thermal behavior of Co/AlCe layered double hydroxide[J]. Solid State Sciences. 2021;111:1293–2558.

    Article  Google Scholar 

  52. Xu T, Zhang J, Chi H, et al. Multifunctional properties of organic-inorganic hybrid nanocomposites based on chitosan derivatives and layered double hydroxides for ocular drug delivery[J]. Acta Biomater. 2016;36:152–63.

    Article  CAS  PubMed  Google Scholar 

  53. Senapati S, Thakur R, Verma SP, et al. Layered double hydroxides as effective carrier for anticancer drugs and tailoring of release rate through interlayer anions[J]. J Control Release. 2016;224:186–98.

    Article  CAS  PubMed  Google Scholar 

  54. Gu Z, Thomas AC, Xu ZP, et al. In vitro sustained release of LMWH from MgAl-layered double hydroxide nanohybrids[J]. Chem Mater. 2008;20(11):3715–22.

    Article  CAS  Google Scholar 

  55. Joy M, Iyengar SJ, Chakraborty J, et al. Layered double hydroxide using hydrothermal treatment: morphology evolution, intercalation and release kinetics of diclofenac sodium[J]. Front Mater Sci. 2017;11(4):395–408.

    Article  Google Scholar 

  56. Wang Y, Cao F, Ping Q. Preparation and properties of diclofenac sodium layered bimetallic hydroxide nanocomplex [J]. J China Pharm Univ. 2009;40(04):321–6.

    Google Scholar 

  57. Chouman De, Niu M, Wang Y, et al. Study on synthesis, microstructure and adsorption properties of nano-sized MG-Al hydrotalcite [J]. J Artif Cryst. 2016;45(04):1047–54.

    Google Scholar 

  58. Iiansong Wu, Xiao Y, Wang J, et al. Growth mechanism of hydrotalcite crystal [J]. Sci China Tech Sci. 2012;42(04):486–92.

    Google Scholar 

  59. Junfang D, Liping L, Ye W, et al. Topological transformation of LDH nanosheets to highly dispersed PtNiFe nanoalloys enhancing CO oxidation performance[J]. Nanoscale. 2020;12(27):14882–94.

    Article  Google Scholar 

  60. Laipan M, Zhu J, Xu Y, et al. Fabrication of layered double hydroxide/carbon nanomaterial for heavy metals removal[J]. Appl Clay Sci. 2020;199:105867.

    Article  CAS  Google Scholar 

  61. Ping XZ, Gregory S, Chao-Qing L, et al. Dispersion and size control of layered double hydroxide nanoparticles in aqueous solutions[J]. J Phys Chem B. 2006;110(34):16923–9.

    Article  Google Scholar 

  62. Chi H, Tingting Xu, Chen H, et al. Study on pynoxine sodium - layered double hydroxide nanosheet and intercalated nanoparticle complex eye drops [J]. J China Pharm Univ. 2016;47(04):448–56.

    Google Scholar 

  63. Kalam MA. The potential application of hyaluronic acid coated chitosan nanoparticles in ocular delivery of dexamethasone[J]. Int J Biol Macromol. 2016;89:559–68.

    Article  PubMed  Google Scholar 

  64. Zhang J, Chi H, Cheng Y, et al. Study on thiol chitosan-pynoxine sodium and layered double hydroxide nanocomposite eye drops [J]. J China Pharm Univ. 2015;46(02):201–8.

    CAS  Google Scholar 

  65. Moustafa MA, Elnaggar YSR, El-Refaie WM, et al. Hyalugel-integrated liposomes as a novel ocular nanosized delivery system of fluconazole with promising prolonged effect. Int J Pharm [J]. 2017;534(1–2):14–24.

    Article  CAS  PubMed  Google Scholar 

  66. Liu C, Lan Q, He W, et al. Octa-arginine modified lipid emulsions as a potential ocular delivery system for disulfiram: a study of the corneal permeation, transcorneal mechanism and anti-cataract effect. Colloids Surf B Biointerfaces [J]. 2017;160:305–14.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors confirmed that this research work did not receive any specific funding.

Author information

Authors and Affiliations

  1. School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, 1, Shenyang, 110016, China

    Donghao Gu, Hao Pan, Shuo Xu, Wenyue Chen, Renfang Zhu, Wenjing Jiang & Weisan Pan

  2. Liaoning University, Shenyang, 110036, China

    Donghao Gu, Hao Pan, Shuo Xu, Wenyue Chen, Renfang Zhu, Wenjing Jiang & Weisan Pan

Authors
  1. Donghao Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hao Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shuo Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wenyue Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Renfang Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wenjing Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Weisan Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Donghao Gu: conceptualization, methodology, formal analysis, investigation, resources, data curation, writing—review and editing, visualization, supervision, project administration; Hao Pan: conceptualization, methodology, formal analysis, investigation, resources, data curation, writing—original draft, visualization, supervision, project administration; Shuo Xu: conceptualization, formal analysis, investigation, data curation; Wenyue Chen: conceptualization, methodology, data, acquisition, formal analysis; Renfang Zu: conceptualization, methodology, formal analysis, data curation; Wenjing Jiang: literature review, writing—original draft, data curation.

Corresponding author

Correspondence to Weisan Pan.

Ethics declarations

Conflict of Interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gu, D., Pan, H., Xu, S. et al. Construction and Evaluation of Hyaluronic Acid–Coated Flurbiprofen-Layered Double Hydroxide Ocular Drug Delivery System. AAPS PharmSciTech 23, 287 (2022). https://doi.org/10.1208/s12249-022-02418-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1208/s12249-022-02418-2

Keywords

Search

Navigation